INTRODUCTION
cell physiology induced by the first events of virus infection (28).
1
In the last few years, many new drugs that act by blocking virus entry have been developed (14, 2 15, 25). Among these, some chemically sulfated derivatives of the K5 capsular polysaccharide from 3 Escherichia coli (E. coli) have emerged as a promising novel class of antiviral compounds. The K5 4 polysaccharide has the same structure of N-acetyl-heparosan, the biosynthetic precursor of heparin. 
13
Two hours post-infection, the inocula were removed, cells were washed, and media containing various 14 concentrations of each compound, 5% FBS, and 0.6% methylcellulose (MC) were added. All 15 compound concentrations were tested at least in duplicate. After incubation for 10-11 days (for HCMV) 16 or 5 days (for MCMV) at 37°C, cell monolayers were stained with crystal violet and viral plaques were 17 counted. Cell-to-cell spread inhibition assays. The ability of K5 derivatives to block HCMV cell-to-cell 11 spread was evaluated as already described (11) nM, respectively) after both 2 and 4 h of incubation (Table 3 and data not shown).
K5-N,OS(L) and K5-N,OS(H) affect the first events of HCMV replication cycle.

21
Next, to test the effects of the K5 derivatives on viral entry, experiments were performed in 22 which HCMV was allowed to pre-attach to cells at 4°C in the absence of compound; various 23 concentrations of test compounds were then added and infected cells were shifted to 37°C for 2 h to permit virus entry. As shown in The sulfated K5 derivatives do not exhibit virucidal activity against HCMV. Cell pre-treatment with sulfated K5 derivatives does not affect HCMV replication.
16
To gain further insights on K5 derivatives mode of action, we investigated whether they could exert Table 4 and Finally, since the emergence of drug-resistant HCMV strains is becoming a problem of major concern 3 in the management of HCMV-infected patients, we tested the activity of the most active derivative, i.e., 4 K5-N,OS(H), against viruses resistant to the current licensed anti-HCMV drugs GCV, CDV, and FOS.
5
As reported in Table 5 , K5-N,OS(H) retained full antiviral activity against both GCV-and FOS- improved efficacy and novel mechanisms of action is still a priority.
9
In this paper, we report the identification of two compounds structurally related to the heparan Table 2 ). In addition, a certain selectivity of K5 derivatives is evident; in fact, Reported values represent the means ± SD of data derived from at least three independent experiments 7 in duplicate. 
